Q3 Earnings Forecast for Prothena Issued By Zacks Research

Prothena Corporation plc (NASDAQ:PRTA) – Zacks Research boosted their Q3 2026 earnings per share estimates for Prothena in a report issued on Thursday, October 16th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.78) per share for the quarter, up from their prior forecast of ($0.87). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($2.42) EPS.

A number of other brokerages have also commented on PRTA. Royal Bank Of Canada cut their price target on Prothena from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. Chardan Capital restated a “buy” rating and issued a $18.00 price target on shares of Prothena in a report on Thursday, August 28th. Piper Sandler lowered their target price on Prothena from $81.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, August 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Prothena in a research report on Wednesday, October 8th. Finally, JMP Securities lowered their price target on Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Tuesday, September 2nd. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.50.

Prothena Price Performance

Shares of Prothena stock opened at $10.22 on Monday. The firm has a market cap of $550.14 million, a price-to-earnings ratio of -1.81 and a beta of -0.11. The stock’s 50-day moving average is $8.99 and its 200-day moving average is $7.78. Prothena has a one year low of $4.32 and a one year high of $18.88.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%.

Hedge Funds Weigh In On Prothena

A number of institutional investors have recently bought and sold shares of the business. CWM LLC raised its stake in Prothena by 650.1% in the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 8,880 shares during the period. Focused Wealth Management Inc boosted its stake in shares of Prothena by 77.8% during the 3rd quarter. Focused Wealth Management Inc now owns 57,129 shares of the biotechnology company’s stock worth $558,000 after acquiring an additional 25,000 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Prothena during the 3rd quarter worth approximately $876,000. Squarepoint Ops LLC bought a new position in shares of Prothena during the 2nd quarter worth approximately $1,270,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Prothena by 571.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 10,815 shares during the period. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.